SlideShare a Scribd company logo
1 of 28
Download to read offline
ANTIBIO:ANTIBIO:
ANTIBIOtic therapyANTIBIOtic therapy
in patients after an acutein patients after an acute
myocardial infarctionmyocardial infarction
an ALKK Studyan ALKK Study
ANTIBIO:ANTIBIO:
ANTIBIOtic therapyANTIBIOtic therapy
in patients after an acutein patients after an acute
myocardial infarctionmyocardial infarction
an ALKK Studyan ALKK Study
R Zahn, B Frilling, S Schneider, U Tebbe, M Weber, M Gottwik,
E Altmann, F Seidel, J Rox, U Höffler, J Senges
for the
Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte
(ALKK)
Background (1)
•Inflammation plays a crucial role in the pathogenesis
of arteriosclerosis.
•Seroepidemiological studies have raised the question
if bacterial infections, especially with Chlamydia
pneumoniae, may contribute to this inflammatory
process.
•Histopathological studies could show a higher
prevalence of Chlamydia pneumoniae in diseased
coronary arteries.
•Animal models also seem to support an active role of
Background (2)
•Therefore therapy with a macrolide antibiotic may
favourably influence the natural course in patients with
coronary heart disease.
•Some small clinical studies in patients with acute
coronary syndromes indicated a potential beneficial
effect of such a treatment
(ROXIS study / study of Gupta et al.).
ANTIBIO
• prospective
• randomised
• placebo controlled
• double-blind
Antibiotic therapy
after an acute myocardial infarction
to investigate the effect of treatment with
roxithromycin in patients with an acute
myocardial infarction (AMI).
ANTIBIO-Study
Principal Investigator
R Zahn
Steering Committee
J Senges (chairman)
U Tebbe
M Weber
KL Neuhaus§
§ Dr. Neuhaus died before the end of the
study
Advisory board
M Gottwik
U Höffler
Data and Safety Monitoring Board
R Schröder (chairman)
W Stille
H Katus
R Dietz
Statistical analysis
S Schneider
KE Siegler
Study coordination
H Dehn
Financial support:
Aventis Pharma gGmbH, Germany
Study design
Acute myocardial infarction (AMI)
hospital admission <48 hours after symptom onset
- exclusion criteria fulfilled
- declined to participate
randomisation
within 5 days after admission
Roxithromycin
300mg/OD for 6 weeks
Placebo
1/OD for 6 weeks
12 months follow-up
AMI diagnosis
•Angina pectoris lasting for >20 minutes
•Elevation of creatinine kinase more than three times the normal
upper with significant CK-MB fraction or
elevation of troponin T or troponin I
•Changes in the electrocardiogram (ECG), either
-ST elevation myocardial infarction
(ST segment elevation of ≥ 1 mm in at least 2 standard leads
or ≥ 2 mm in at least 2 contiguous precordial leads or the
presence of a left bundle branch block) or
-ST segment depression of > 1mm in two contiguous leads or
inversion of the T waves of > 1mm in at least 3 contiguous
End points
•Primary endpoint was
total mortality at 12 months
•Secondary endpoints were a
-combined endpoint of death, reinfarction,
resuscitation, stroke or postinfarction angina at
hospital discharge
-combined endpoint of death, reinfarction,
resuscitation, stroke or unstable angina pectoris
leading to hospital admission at 12 months
-the rate of percutaneous coronary intervention
(PCI) or coronary artery bypass surgery (CABG)
at 12 months
Statistics
•A total mortality rate after 12 months of 10% in the placebo
group and a 30% lower mortality rate in the active treatment
group (7% mortality) were assumed.
•For safety reasons total mortality at 8 weeks after randomisation
was monitored in a sequential design (triangular test) according
to the ´restricted procedure´ method reported by Whitehead.
•The proposed decision to stop the study was based on 1%
significance level for differences in total 8 week mortality.
•The total test level was therefore adjusted according to
Bonferroni´s method to a two sided α-level of 4%, with an 80%
power to detect a significant difference. This resulted in a
Statistics
•Primarily all analyses were performed on an
intention-to-treat basis.
•Afterwards, endpoints were analysed
after adjusting for differences in base-line
characteristics (logistic regression analysis).
•Furthermore data were analysed on a
“treatment-per-protocol” basis.
68 participating centers (ALKK)
Results (1)
•Inclusion of patients started on September 1999,
end of inclusion was planned for 12/2000.
•After continuous slow recruitment of patients,
end of inclusion was extended to 4/2001.
•4/2001 the steering committee decided to stop the study
•872 patients were included,
433 treated with roxithromycin and
439 with placebo
randomised patients
n=872
roxithromycin
n=433 (100%)
placebo
n=439 (100%)
completed < 4 of 6 weeks treatment
n= 78 (18%)
completed < 4 of 6 weeks treatment
n=48 (11 %)
12 month follow-up
n=431 (99.5%)
12 month follow-up
n=437 (99.5%)
lost for follow-up :
n=2
lost for follow-up:
n= 2
Results (2)
p=0.003
Patients characteristics
roxithromycin
n = 433
placebo
n = 439
p-value
age (years) 60.4 61.0 0.689
male gender 79.0% 79.5% 0.851
STEMI 87.1% 88.8% 0.422
anterior wall MI* 48.1% 40.2% 0.027
cardiogenic shock 3.0% 3.9% 0.469
heart failure at ad 8.6% 8.5% 0.967
resuscitation 3.9% 3.6% 0.828
LBBB 1.2% 1.8% 0.418
atrial fibrillation 5.8% 4.3% 0.329
*in case of STEMI
Concomitant diseases
roxithromycin
n = 433
placebo
n = 439
p-value
renal failure 5.2% 3.9% 0.392
COPD 3.5% 6.9% 0.028
arterial hypert. 49.7% 53.5% 0.260
diabetes mellitus 15.9% 16.4% 0.816
Reperfusion therapy
roxithromycin
n = 433
placebo
n = 439
p-value
any reperfusion
therapy
71.4% 69.5% 0.542
reperfusion therapy
in STEMI
76.1% 73.9% 0.466
angioplasty in
STEMI
45.1% 43.3% 0.624
thrombolysis in
STEMI
41.9% 39.0% 0.408
88% ST elevation myocardial infarction
Medication <48h after ad.
roxithromycin
n = 433
placebo
n = 439
p-value
aspirin 98.9% 98.6% 0.779
IIb/IIIa antagonists 37.6% 35.4% 0.489
ß - blockers 89.6% 87.5% 0.322
ACE inhibitors 74.1% 71.5% 0.387
other antibiotics 3.5% 5.0% 0.260
Medication at discharge
roxithromycin
n = 425
placebo
n = 431
p-value
aspirin 92.9% 93.3% 0.849
clopidogrel/ticlopidine 50.2% 50.8% 0.866
statins 75.5% 72.6% 0.332
ß - blockers 92% 91% 0.583
ACE inhibitors 80.9% 79.8% 0.678
Mortality: 12-months
6,5
6
0
1
2
3
4
5
6
7
8
9
10
roxithromycin placebo
mortality(%)
p=0.739
Kaplan-Meier survival curve
months after randomisation
Survival
no EPS response
0 1 2 3 4 5 6 7 8 9 10 11 12
0,7
0,75
0,8
0,85
0,9
0,95
1
Placebo
Roxithromycin
p=0.86
combined endpoint: hospital
18,7
14,1
0
2
4
6
8
10
12
14
16
18
20
roxithromycin placebo
combinedendpoint(%)
p=0.068
death, MI, resuscitation, stroke, postinfarction angina
combined endpoint: 12-months
27,8
23,2
0
5
10
15
20
25
30
roxithromycin placebo
combinedendpoint(%)
p=0.110
death, MI, resuscitation, stroke, angina leading to hosp.
endpoints: 12-months
1,6
4,9
16,9
6 5,5
2,1
3,4
13,3
6,5
4,9
0
2
4
6
8
10
12
14
16
18
20
death MI stroke resusc. UA
(%)
roxithromycin placebo
p=ns
CABG/PTCA: 12-months
56 53,3
0
10
20
30
40
50
60
roxithromycin placebo
CABG/PTCA(%)
p=0.621
endpoints: 12-months
56
7,1
24,4
55,5
6
23,2
53,3
6,2
20,8
51
6,5
27,8
0
10
20
30
40
50
60
death CE revasc death CE revasc
(%)
roxithromycin placebo
all p=ns
intention-to-treat treatment-per-protocol
endpoints: disch - 12-months
25,1
5,1
11,6
23,2
4,1
11,2
23,1
4,4
21,2
4,6
11,6 11,5
0
5
10
15
20
25
30
death CE revasc death CE revasc
(%)
roxithromycin placebo
all p=ns
intention-to-treat treatment-per-protocol
Summary (1)
•In patients with an AMI, 6 week treatment with
roxithromycin (300mg/OD) did not result in a
significant reduction in 12-month mortality or
morbidity.
•Results did not change if the analyses were performed
on an „intention-to-treat“, „treatment-per-protocol“
basis or after adjustment for differences in patients
characteristics.
Summary (2)
•Despite the premature termination of our study after
872 patients instead of the intended 3922 patients,
our results make it very unlikely, that we missed a
clinically relevant benefit of treatment with
roxithromycin.
•Therefore routine treatment with roxithromycin
in AMI patients can not be advised.

More Related Content

What's hot

Reducing Hospital Readmissions for Heart Failure
Reducing Hospital Readmissions for Heart FailureReducing Hospital Readmissions for Heart Failure
Reducing Hospital Readmissions for Heart FailureVSee
 
Classical Hodgkin’s lymphoma
Classical Hodgkin’s lymphomaClassical Hodgkin’s lymphoma
Classical Hodgkin’s lymphomaAnkit Raiyani
 
Warfarin related nephropathy; Evidence Based Medicine
Warfarin related nephropathy; Evidence Based MedicineWarfarin related nephropathy; Evidence Based Medicine
Warfarin related nephropathy; Evidence Based MedicineWisit Cheungpasitporn
 
MYELOFIBROSIS: SERGE VERSTOVSEK
MYELOFIBROSIS: SERGE VERSTOVSEKMYELOFIBROSIS: SERGE VERSTOVSEK
MYELOFIBROSIS: SERGE VERSTOVSEKspa718
 
Presentation reducing readmissions 2019
Presentation  reducing  readmissions 2019 Presentation  reducing  readmissions 2019
Presentation reducing readmissions 2019 Imad Hassan
 
Dabigatran vs warfain Prior to TEE Journal Club
Dabigatran vs warfain Prior to TEE Journal ClubDabigatran vs warfain Prior to TEE Journal Club
Dabigatran vs warfain Prior to TEE Journal ClubMichael Katz
 
Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates Praveen Nagula
 
Betablocker in chronic stable angina 24-01-2013.
Betablocker in chronic stable angina 24-01-2013.Betablocker in chronic stable angina 24-01-2013.
Betablocker in chronic stable angina 24-01-2013.Ramachandra Barik
 
Intensive Insulin Therapy In The Medical Icu
Intensive Insulin Therapy In The Medical IcuIntensive Insulin Therapy In The Medical Icu
Intensive Insulin Therapy In The Medical IcuNadSamm
 
TKI discontinuation in CML
TKI discontinuation in CMLTKI discontinuation in CML
TKI discontinuation in CMLspa718
 
Recent Advances In The Development Of Innovative Therapies The Celgene Pipeline
Recent Advances In The Development  Of Innovative Therapies The Celgene PipelineRecent Advances In The Development  Of Innovative Therapies The Celgene Pipeline
Recent Advances In The Development Of Innovative Therapies The Celgene Pipelinespa718
 
Kappos fingolimod moa-clin_results_vfinal_buenosaires1a
Kappos fingolimod moa-clin_results_vfinal_buenosaires1aKappos fingolimod moa-clin_results_vfinal_buenosaires1a
Kappos fingolimod moa-clin_results_vfinal_buenosaires1arubenroa
 
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome PatientsStrategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome PatientsPERKI Pekanbaru
 
Journal club 11 1-2012 woest trial
Journal club 11 1-2012 woest trialJournal club 11 1-2012 woest trial
Journal club 11 1-2012 woest trialMichael Katz
 
Htn combination portsaid
Htn combination portsaidHtn combination portsaid
Htn combination portsaidMahmoud Yossof
 
Biomarkers in Heart Failure
Biomarkers in Heart FailureBiomarkers in Heart Failure
Biomarkers in Heart FailureEdgar Hernández
 
Relapsed Myeloma
Relapsed MyelomaRelapsed Myeloma
Relapsed Myelomaspa718
 

What's hot (20)

Reducing Hospital Readmissions for Heart Failure
Reducing Hospital Readmissions for Heart FailureReducing Hospital Readmissions for Heart Failure
Reducing Hospital Readmissions for Heart Failure
 
Classical Hodgkin’s lymphoma
Classical Hodgkin’s lymphomaClassical Hodgkin’s lymphoma
Classical Hodgkin’s lymphoma
 
Warfarin related nephropathy; Evidence Based Medicine
Warfarin related nephropathy; Evidence Based MedicineWarfarin related nephropathy; Evidence Based Medicine
Warfarin related nephropathy; Evidence Based Medicine
 
MYELOFIBROSIS: SERGE VERSTOVSEK
MYELOFIBROSIS: SERGE VERSTOVSEKMYELOFIBROSIS: SERGE VERSTOVSEK
MYELOFIBROSIS: SERGE VERSTOVSEK
 
Presentation reducing readmissions 2019
Presentation  reducing  readmissions 2019 Presentation  reducing  readmissions 2019
Presentation reducing readmissions 2019
 
Dabigatran vs warfain Prior to TEE Journal Club
Dabigatran vs warfain Prior to TEE Journal ClubDabigatran vs warfain Prior to TEE Journal Club
Dabigatran vs warfain Prior to TEE Journal Club
 
Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates
 
Betablocker in chronic stable angina 24-01-2013.
Betablocker in chronic stable angina 24-01-2013.Betablocker in chronic stable angina 24-01-2013.
Betablocker in chronic stable angina 24-01-2013.
 
Reinfarction after thrombolytics
Reinfarction after thrombolyticsReinfarction after thrombolytics
Reinfarction after thrombolytics
 
Intensive Insulin Therapy In The Medical Icu
Intensive Insulin Therapy In The Medical IcuIntensive Insulin Therapy In The Medical Icu
Intensive Insulin Therapy In The Medical Icu
 
TKI discontinuation in CML
TKI discontinuation in CMLTKI discontinuation in CML
TKI discontinuation in CML
 
Recent Advances In The Development Of Innovative Therapies The Celgene Pipeline
Recent Advances In The Development  Of Innovative Therapies The Celgene PipelineRecent Advances In The Development  Of Innovative Therapies The Celgene Pipeline
Recent Advances In The Development Of Innovative Therapies The Celgene Pipeline
 
Kappos fingolimod moa-clin_results_vfinal_buenosaires1a
Kappos fingolimod moa-clin_results_vfinal_buenosaires1aKappos fingolimod moa-clin_results_vfinal_buenosaires1a
Kappos fingolimod moa-clin_results_vfinal_buenosaires1a
 
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome PatientsStrategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
 
Journal club 11 1-2012 woest trial
Journal club 11 1-2012 woest trialJournal club 11 1-2012 woest trial
Journal club 11 1-2012 woest trial
 
AHA: EMPHASIS-HF Trial
AHA: EMPHASIS-HF TrialAHA: EMPHASIS-HF Trial
AHA: EMPHASIS-HF Trial
 
Htn combination portsaid
Htn combination portsaidHtn combination portsaid
Htn combination portsaid
 
oral drugs in multiple sclerosis
oral drugs in multiple sclerosisoral drugs in multiple sclerosis
oral drugs in multiple sclerosis
 
Biomarkers in Heart Failure
Biomarkers in Heart FailureBiomarkers in Heart Failure
Biomarkers in Heart Failure
 
Relapsed Myeloma
Relapsed MyelomaRelapsed Myeloma
Relapsed Myeloma
 

Viewers also liked

Dr. Mike Apley - Antibiotic Stewardship and Animal Agriculture
Dr. Mike Apley - Antibiotic Stewardship and Animal AgricultureDr. Mike Apley - Antibiotic Stewardship and Animal Agriculture
Dr. Mike Apley - Antibiotic Stewardship and Animal AgricultureJohn Blue
 
TruCare Pharmacy Veterinary Tips: Frightened Dogs
TruCare Pharmacy Veterinary Tips: Frightened DogsTruCare Pharmacy Veterinary Tips: Frightened Dogs
TruCare Pharmacy Veterinary Tips: Frightened DogsTruCare Pharmacy
 
Antibiotic selection /certified fixed orthodontic courses by Indian dental ...
Antibiotic selection   /certified fixed orthodontic courses by Indian dental ...Antibiotic selection   /certified fixed orthodontic courses by Indian dental ...
Antibiotic selection /certified fixed orthodontic courses by Indian dental ...Indian dental academy
 
Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"
Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"
Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"Edward Brant DDS, MS
 
systemic anti-microbials in periodontal therapy
systemic anti-microbials in periodontal therapysystemic anti-microbials in periodontal therapy
systemic anti-microbials in periodontal therapyMehul Shinde
 
Antibiotic resistance -aveen omer
Antibiotic resistance -aveen omerAntibiotic resistance -aveen omer
Antibiotic resistance -aveen omerAveenOmer
 
Antibiotics in dentistry
Antibiotics in dentistryAntibiotics in dentistry
Antibiotics in dentistryUzair86
 
Applications of antibiotics in dentistry /endodontic courses
Applications of antibiotics in dentistry /endodontic coursesApplications of antibiotics in dentistry /endodontic courses
Applications of antibiotics in dentistry /endodontic coursesIndian dental academy
 
Antibiotics used in peridontal diseases(1)
Antibiotics used in peridontal diseases(1)Antibiotics used in peridontal diseases(1)
Antibiotics used in peridontal diseases(1)Hafsa Zubair
 
Therapeutics in dentistry (antibiotics)
Therapeutics in dentistry (antibiotics) Therapeutics in dentistry (antibiotics)
Therapeutics in dentistry (antibiotics) Iyad Abou Rabii
 
Antibiotics in ophthalmology
Antibiotics in ophthalmologyAntibiotics in ophthalmology
Antibiotics in ophthalmologySamten Dorji
 
Antibiotics used in periodontics
Antibiotics used in periodonticsAntibiotics used in periodontics
Antibiotics used in periodonticsshashi chaudhary
 
Common Antibiotics : Used in periodontal therapy, easy approach for therapeut...
Common Antibiotics : Used in periodontal therapy, easy approach for therapeut...Common Antibiotics : Used in periodontal therapy, easy approach for therapeut...
Common Antibiotics : Used in periodontal therapy, easy approach for therapeut...DrUshaVyasBohra
 
Veterinary pharmacy
Veterinary pharmacyVeterinary pharmacy
Veterinary pharmacyNES
 
3rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 13rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 1SHAPE Society
 
510 does lxr links lipid metabolism to inflammation, or ppar
510 does lxr links lipid metabolism to inflammation, or ppar510 does lxr links lipid metabolism to inflammation, or ppar
510 does lxr links lipid metabolism to inflammation, or pparSHAPE Society
 

Viewers also liked (20)

Dr. Mike Apley - Antibiotic Stewardship and Animal Agriculture
Dr. Mike Apley - Antibiotic Stewardship and Animal AgricultureDr. Mike Apley - Antibiotic Stewardship and Animal Agriculture
Dr. Mike Apley - Antibiotic Stewardship and Animal Agriculture
 
TruCare Pharmacy Veterinary Tips: Frightened Dogs
TruCare Pharmacy Veterinary Tips: Frightened DogsTruCare Pharmacy Veterinary Tips: Frightened Dogs
TruCare Pharmacy Veterinary Tips: Frightened Dogs
 
Antibiotic selection /certified fixed orthodontic courses by Indian dental ...
Antibiotic selection   /certified fixed orthodontic courses by Indian dental ...Antibiotic selection   /certified fixed orthodontic courses by Indian dental ...
Antibiotic selection /certified fixed orthodontic courses by Indian dental ...
 
Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"
Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"
Long Island Periodontist presents "Appropriate Use of Antibiotics In Dentistry"
 
systemic anti-microbials in periodontal therapy
systemic anti-microbials in periodontal therapysystemic anti-microbials in periodontal therapy
systemic anti-microbials in periodontal therapy
 
Antibiotic resistance -aveen omer
Antibiotic resistance -aveen omerAntibiotic resistance -aveen omer
Antibiotic resistance -aveen omer
 
Antibiotics in dentistry
Antibiotics in dentistryAntibiotics in dentistry
Antibiotics in dentistry
 
Applications of antibiotics in dentistry /endodontic courses
Applications of antibiotics in dentistry /endodontic coursesApplications of antibiotics in dentistry /endodontic courses
Applications of antibiotics in dentistry /endodontic courses
 
Antibiotics used in peridontal diseases(1)
Antibiotics used in peridontal diseases(1)Antibiotics used in peridontal diseases(1)
Antibiotics used in peridontal diseases(1)
 
Therapeutics in dentistry (antibiotics)
Therapeutics in dentistry (antibiotics) Therapeutics in dentistry (antibiotics)
Therapeutics in dentistry (antibiotics)
 
Antibiotics in ophthalmology
Antibiotics in ophthalmologyAntibiotics in ophthalmology
Antibiotics in ophthalmology
 
Antibiotics in Endodontics
Antibiotics in EndodonticsAntibiotics in Endodontics
Antibiotics in Endodontics
 
Antibiotics used in periodontics
Antibiotics used in periodonticsAntibiotics used in periodontics
Antibiotics used in periodontics
 
Common Antibiotics : Used in periodontal therapy, easy approach for therapeut...
Common Antibiotics : Used in periodontal therapy, easy approach for therapeut...Common Antibiotics : Used in periodontal therapy, easy approach for therapeut...
Common Antibiotics : Used in periodontal therapy, easy approach for therapeut...
 
Veterinary pharmacy
Veterinary pharmacyVeterinary pharmacy
Veterinary pharmacy
 
3rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 13rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 1
 
138 new vp website
138 new vp website138 new vp website
138 new vp website
 
8
88
8
 
254 nanotechnology
254 nanotechnology254 nanotechnology
254 nanotechnology
 
510 does lxr links lipid metabolism to inflammation, or ppar
510 does lxr links lipid metabolism to inflammation, or ppar510 does lxr links lipid metabolism to inflammation, or ppar
510 does lxr links lipid metabolism to inflammation, or ppar
 

Similar to 215 antibio

Hypertension management- Angina IHD
Hypertension management- Angina IHDHypertension management- Angina IHD
Hypertension management- Angina IHDcardiositeindia
 
FIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxFIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxdrsbansal2000
 
Effect of hydrocortisone on development of shock among
Effect of hydrocortisone on development of shock amongEffect of hydrocortisone on development of shock among
Effect of hydrocortisone on development of shock amongDr fakhir Raza
 
Hot Topics in Critical Care - March 2017
Hot Topics in Critical Care - March 2017Hot Topics in Critical Care - March 2017
Hot Topics in Critical Care - March 2017Steve Mathieu
 
Emergency rt for nurse
Emergency rt for nurseEmergency rt for nurse
Emergency rt for nursetechno UCH
 
revasularisation of acute stroke.pptx
revasularisation of acute stroke.pptxrevasularisation of acute stroke.pptx
revasularisation of acute stroke.pptxvinay nandimalla
 
Evolving landscape in the management of Acute Ischemic Stroke
Evolving landscape in the management of Acute Ischemic StrokeEvolving landscape in the management of Acute Ischemic Stroke
Evolving landscape in the management of Acute Ischemic StrokePramod Krishnan
 
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center GeorgiaHeart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgiamelvillejackson
 
Ami Selayang Hospital
Ami Selayang HospitalAmi Selayang Hospital
Ami Selayang HospitalRashidi Ahmad
 
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxEffect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxNayyarSaleem2
 
Stroke update 2011
Stroke update 2011Stroke update 2011
Stroke update 2011taem
 
Empagliflozin in acute myocardial infarction.pptx
Empagliflozin in acute myocardial infarction.pptxEmpagliflozin in acute myocardial infarction.pptx
Empagliflozin in acute myocardial infarction.pptxpurraSameer
 
Beta blocker in acute mi
Beta blocker in acute miBeta blocker in acute mi
Beta blocker in acute miVatsal Kayal
 
Sepsis 2009 update final
Sepsis 2009 update finalSepsis 2009 update final
Sepsis 2009 update finalTroy Pennington
 
Caso clínico líquidos en neuroanestesia
Caso clínico líquidos en neuroanestesiaCaso clínico líquidos en neuroanestesia
Caso clínico líquidos en neuroanestesiaSocundianeste
 

Similar to 215 antibio (20)

Journal club
Journal clubJournal club
Journal club
 
Hypertension management- Angina IHD
Hypertension management- Angina IHDHypertension management- Angina IHD
Hypertension management- Angina IHD
 
FIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxFIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptx
 
Effect of hydrocortisone on development of shock among
Effect of hydrocortisone on development of shock amongEffect of hydrocortisone on development of shock among
Effect of hydrocortisone on development of shock among
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
 
Hot Topics in Critical Care - March 2017
Hot Topics in Critical Care - March 2017Hot Topics in Critical Care - March 2017
Hot Topics in Critical Care - March 2017
 
Emergency rt for nurse
Emergency rt for nurseEmergency rt for nurse
Emergency rt for nurse
 
revasularisation of acute stroke.pptx
revasularisation of acute stroke.pptxrevasularisation of acute stroke.pptx
revasularisation of acute stroke.pptx
 
Evolving landscape in the management of Acute Ischemic Stroke
Evolving landscape in the management of Acute Ischemic StrokeEvolving landscape in the management of Acute Ischemic Stroke
Evolving landscape in the management of Acute Ischemic Stroke
 
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center GeorgiaHeart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
 
Ami Selayang Hospital
Ami Selayang HospitalAmi Selayang Hospital
Ami Selayang Hospital
 
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxEffect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
 
Enoxa vs placebo.pptx
Enoxa vs placebo.pptxEnoxa vs placebo.pptx
Enoxa vs placebo.pptx
 
Stroke update 2011
Stroke update 2011Stroke update 2011
Stroke update 2011
 
Empagliflozin in acute myocardial infarction.pptx
Empagliflozin in acute myocardial infarction.pptxEmpagliflozin in acute myocardial infarction.pptx
Empagliflozin in acute myocardial infarction.pptx
 
Beta blocker in acute mi
Beta blocker in acute miBeta blocker in acute mi
Beta blocker in acute mi
 
Prof. Mahon aip lmc_festa10anni_05_10_2019
Prof. Mahon aip lmc_festa10anni_05_10_2019Prof. Mahon aip lmc_festa10anni_05_10_2019
Prof. Mahon aip lmc_festa10anni_05_10_2019
 
Sepsis 2009 update final
Sepsis 2009 update finalSepsis 2009 update final
Sepsis 2009 update final
 
CATIS trial
CATIS trialCATIS trial
CATIS trial
 
Caso clínico líquidos en neuroanestesia
Caso clínico líquidos en neuroanestesiaCaso clínico líquidos en neuroanestesia
Caso clínico líquidos en neuroanestesia
 

More from SHAPE Society

Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stoneSHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 fSHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)SHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for printSHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for printSHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermographySHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st centurySHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosisSHAPE Society
 

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Braunwald
BraunwaldBraunwald
Braunwald
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
103100
103100103100
103100
 

Recently uploaded

NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdfHongBiThi1
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONojaswinihemane
 

Recently uploaded (20)

NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
 

215 antibio

  • 1. ANTIBIO:ANTIBIO: ANTIBIOtic therapyANTIBIOtic therapy in patients after an acutein patients after an acute myocardial infarctionmyocardial infarction an ALKK Studyan ALKK Study ANTIBIO:ANTIBIO: ANTIBIOtic therapyANTIBIOtic therapy in patients after an acutein patients after an acute myocardial infarctionmyocardial infarction an ALKK Studyan ALKK Study R Zahn, B Frilling, S Schneider, U Tebbe, M Weber, M Gottwik, E Altmann, F Seidel, J Rox, U Höffler, J Senges for the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
  • 2. Background (1) •Inflammation plays a crucial role in the pathogenesis of arteriosclerosis. •Seroepidemiological studies have raised the question if bacterial infections, especially with Chlamydia pneumoniae, may contribute to this inflammatory process. •Histopathological studies could show a higher prevalence of Chlamydia pneumoniae in diseased coronary arteries. •Animal models also seem to support an active role of
  • 3. Background (2) •Therefore therapy with a macrolide antibiotic may favourably influence the natural course in patients with coronary heart disease. •Some small clinical studies in patients with acute coronary syndromes indicated a potential beneficial effect of such a treatment (ROXIS study / study of Gupta et al.).
  • 4. ANTIBIO • prospective • randomised • placebo controlled • double-blind Antibiotic therapy after an acute myocardial infarction to investigate the effect of treatment with roxithromycin in patients with an acute myocardial infarction (AMI).
  • 5. ANTIBIO-Study Principal Investigator R Zahn Steering Committee J Senges (chairman) U Tebbe M Weber KL Neuhaus§ § Dr. Neuhaus died before the end of the study Advisory board M Gottwik U Höffler Data and Safety Monitoring Board R Schröder (chairman) W Stille H Katus R Dietz Statistical analysis S Schneider KE Siegler Study coordination H Dehn Financial support: Aventis Pharma gGmbH, Germany
  • 6. Study design Acute myocardial infarction (AMI) hospital admission <48 hours after symptom onset - exclusion criteria fulfilled - declined to participate randomisation within 5 days after admission Roxithromycin 300mg/OD for 6 weeks Placebo 1/OD for 6 weeks 12 months follow-up
  • 7. AMI diagnosis •Angina pectoris lasting for >20 minutes •Elevation of creatinine kinase more than three times the normal upper with significant CK-MB fraction or elevation of troponin T or troponin I •Changes in the electrocardiogram (ECG), either -ST elevation myocardial infarction (ST segment elevation of ≥ 1 mm in at least 2 standard leads or ≥ 2 mm in at least 2 contiguous precordial leads or the presence of a left bundle branch block) or -ST segment depression of > 1mm in two contiguous leads or inversion of the T waves of > 1mm in at least 3 contiguous
  • 8. End points •Primary endpoint was total mortality at 12 months •Secondary endpoints were a -combined endpoint of death, reinfarction, resuscitation, stroke or postinfarction angina at hospital discharge -combined endpoint of death, reinfarction, resuscitation, stroke or unstable angina pectoris leading to hospital admission at 12 months -the rate of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) at 12 months
  • 9. Statistics •A total mortality rate after 12 months of 10% in the placebo group and a 30% lower mortality rate in the active treatment group (7% mortality) were assumed. •For safety reasons total mortality at 8 weeks after randomisation was monitored in a sequential design (triangular test) according to the ´restricted procedure´ method reported by Whitehead. •The proposed decision to stop the study was based on 1% significance level for differences in total 8 week mortality. •The total test level was therefore adjusted according to Bonferroni´s method to a two sided α-level of 4%, with an 80% power to detect a significant difference. This resulted in a
  • 10. Statistics •Primarily all analyses were performed on an intention-to-treat basis. •Afterwards, endpoints were analysed after adjusting for differences in base-line characteristics (logistic regression analysis). •Furthermore data were analysed on a “treatment-per-protocol” basis.
  • 12. Results (1) •Inclusion of patients started on September 1999, end of inclusion was planned for 12/2000. •After continuous slow recruitment of patients, end of inclusion was extended to 4/2001. •4/2001 the steering committee decided to stop the study •872 patients were included, 433 treated with roxithromycin and 439 with placebo
  • 13. randomised patients n=872 roxithromycin n=433 (100%) placebo n=439 (100%) completed < 4 of 6 weeks treatment n= 78 (18%) completed < 4 of 6 weeks treatment n=48 (11 %) 12 month follow-up n=431 (99.5%) 12 month follow-up n=437 (99.5%) lost for follow-up : n=2 lost for follow-up: n= 2 Results (2) p=0.003
  • 14. Patients characteristics roxithromycin n = 433 placebo n = 439 p-value age (years) 60.4 61.0 0.689 male gender 79.0% 79.5% 0.851 STEMI 87.1% 88.8% 0.422 anterior wall MI* 48.1% 40.2% 0.027 cardiogenic shock 3.0% 3.9% 0.469 heart failure at ad 8.6% 8.5% 0.967 resuscitation 3.9% 3.6% 0.828 LBBB 1.2% 1.8% 0.418 atrial fibrillation 5.8% 4.3% 0.329 *in case of STEMI
  • 15. Concomitant diseases roxithromycin n = 433 placebo n = 439 p-value renal failure 5.2% 3.9% 0.392 COPD 3.5% 6.9% 0.028 arterial hypert. 49.7% 53.5% 0.260 diabetes mellitus 15.9% 16.4% 0.816
  • 16. Reperfusion therapy roxithromycin n = 433 placebo n = 439 p-value any reperfusion therapy 71.4% 69.5% 0.542 reperfusion therapy in STEMI 76.1% 73.9% 0.466 angioplasty in STEMI 45.1% 43.3% 0.624 thrombolysis in STEMI 41.9% 39.0% 0.408 88% ST elevation myocardial infarction
  • 17. Medication <48h after ad. roxithromycin n = 433 placebo n = 439 p-value aspirin 98.9% 98.6% 0.779 IIb/IIIa antagonists 37.6% 35.4% 0.489 ß - blockers 89.6% 87.5% 0.322 ACE inhibitors 74.1% 71.5% 0.387 other antibiotics 3.5% 5.0% 0.260
  • 18. Medication at discharge roxithromycin n = 425 placebo n = 431 p-value aspirin 92.9% 93.3% 0.849 clopidogrel/ticlopidine 50.2% 50.8% 0.866 statins 75.5% 72.6% 0.332 ß - blockers 92% 91% 0.583 ACE inhibitors 80.9% 79.8% 0.678
  • 20. Kaplan-Meier survival curve months after randomisation Survival no EPS response 0 1 2 3 4 5 6 7 8 9 10 11 12 0,7 0,75 0,8 0,85 0,9 0,95 1 Placebo Roxithromycin p=0.86
  • 21. combined endpoint: hospital 18,7 14,1 0 2 4 6 8 10 12 14 16 18 20 roxithromycin placebo combinedendpoint(%) p=0.068 death, MI, resuscitation, stroke, postinfarction angina
  • 22. combined endpoint: 12-months 27,8 23,2 0 5 10 15 20 25 30 roxithromycin placebo combinedendpoint(%) p=0.110 death, MI, resuscitation, stroke, angina leading to hosp.
  • 25. endpoints: 12-months 56 7,1 24,4 55,5 6 23,2 53,3 6,2 20,8 51 6,5 27,8 0 10 20 30 40 50 60 death CE revasc death CE revasc (%) roxithromycin placebo all p=ns intention-to-treat treatment-per-protocol
  • 26. endpoints: disch - 12-months 25,1 5,1 11,6 23,2 4,1 11,2 23,1 4,4 21,2 4,6 11,6 11,5 0 5 10 15 20 25 30 death CE revasc death CE revasc (%) roxithromycin placebo all p=ns intention-to-treat treatment-per-protocol
  • 27. Summary (1) •In patients with an AMI, 6 week treatment with roxithromycin (300mg/OD) did not result in a significant reduction in 12-month mortality or morbidity. •Results did not change if the analyses were performed on an „intention-to-treat“, „treatment-per-protocol“ basis or after adjustment for differences in patients characteristics.
  • 28. Summary (2) •Despite the premature termination of our study after 872 patients instead of the intended 3922 patients, our results make it very unlikely, that we missed a clinically relevant benefit of treatment with roxithromycin. •Therefore routine treatment with roxithromycin in AMI patients can not be advised.